77.37 -0.38 (-0.49%)
After hours: 5:00PM EDT
|Bid||76.66 x 800|
|Ask||78.03 x 2200|
|Day's Range||77.24 - 77.84|
|52 Week Range||60.78 - 78.38|
|PE Ratio (TTM)||47.35|
|Earnings Date||Oct 31, 2018|
|Forward Dividend & Yield||0.76 (0.98%)|
|1y Target Est||79.62|
Known for correctly identifying speculative market bubbles, Grantham Mayo Van Otterloo leader Jeremy Grantham (Trades, Portfolio) has a reputation for steering his clients' assets clear of impending crashes. Warning! GuruFocus has detected 7 Warning Signs with BAX. As of the second quarter, five stocks Grantham keeps buying are Baxter International Inc. (BAX), Freeport-McMoRan Inc. (FCX), GlaxoSmithKline PLC (GSK), Royal Bank of Canada (RY) and SK Telecom Co. Ltd. (SKM).
Baxter International Inc. (BAX), a leading global medical products company, will host a conference call to discuss its third quarter 2018 financial results on Wednesday, October 31, 2018, at 7:30 a.m. Central Time. To access the call, dial (844) 886-1929 (domestic) or (225) 239-4663 (international). Please dial into the call at least ten minutes prior to the start for the operator to connect you. The Conference ID is 9895268.
On September 18, Abbott Laboratories (ABT) ended the trading day at $68.41, up ~1.1% from its previous trading day’s closing price. The stock has maintained growth momentum over the last year.
Its net loss per share was $0.83 in the second quarter of 2017. Of the ten analysts covering uniQure in September, three have given the stock a “strong buy,” and seven have given it a “buy.” The mean rating for the stock is 1.7 with a target price of $49.56, implying an upside potential of 20.1% over uniQure’s closing price of $41.25 on September 13. In comparison, peers Baxter International (BAX), Sanofi (SNY), and Shire (SHPG) have mean ratings of 2.31, 1.8, and 1.83, respectively, and target prices of $79.62, $48.67, and $201.82, respectively.
Baxter International Inc. (BAX), a leading global medical products company, today announced that it has been named to the Dow Jones Sustainability World Index (DJSI World Index) and the Dow Jones Sustainability North America Index (DJSI North America) for the 19th consecutive year. Baxter was recognized this year for its industry-leading performance in the following categories: policy influence, marketing practices, environmental reporting, human rights and occupational health and safety.
Baxter International Inc. (BAX), a global leader in advancing surgical innovation, today announced U.S. Food and Drug Administration (FDA) clearance of Actifuse Flow Bone Graft Substitute for use in a variety of orthopedic surgical procedures. As the newest addition to Baxter’s growing osteobiologics surgery portfolio, Actifuse Flow offers accelerated bone growth in a new, easy-to-use, prepackaged delivery syringe for precise placement into small bony voids or gaps in the skeletal system. Actifuse Flow utilizes the proprietary silicate-substituted technology of Baxter’s Actifuse Bone Graft Substitute, which enhances silicon levels to accelerate bone formation1.
Baxter's (BAX) cyclophosphamide performance continues to remain dismal. Nevertheless, the company witnesses positive tidings of other products on the regulatory front.
DEERFIELD, Ill.-- -- Highest protein and lowest glucose formulation among Parenteral Nutrition products, available in a standardized, triple-chamber bag 1,2,3,4 New PN formulation will help meet needs of high stress patients who require more protein and are often impacted by hyperglycemia OLIMEL 7.6% is the latest addition to Baxter’s olive oil-based parenteral nutrition portfolio Currently approved ...
This analysis is intended to introduce important early concepts to people who are starting to invest and want to begin learning about how to value company based on its currentRead More...
In the first quarter of fiscal 2019, Medtronic’s (MDT) Minimally Invasive Therapies Group reported revenue of $2.1 billion compared to $2.5 billion in the fiscal first quarter of 2018, reflecting a ~17% YoY (year-over-year) fall.
In 2012, Baxter International (BAX) adopted a $2 billion share buyback program. In November 2016 and February 2018, the company increased the program by $1.5 billion each.
Sales from Baxter International’s (BAX) advanced surgery business, which includes biological products and medical devices that are used in surgical procedures, increased from $178 million in the second quarter of 2017 to $204 million in the second quarter of 2018. The marketing and administrative expenses incurred by Baxter International increased from $630 million in the second quarter of 2017 to $681 million in the second quarter of 2018.
Baxter International’s (BAX) global business units include renal care, medication delivery, pharmaceuticals, nutrition, advanced surgery, acute therapies, and other, which primarily includes sales from Baxter’s pharmaceutical partnering business. Baxter International generated revenue of $2.84 billion in the second quarter compared to $2.6 billion in the comparable period in 2017. Baxter International incurred a cost of sales of $1.6 billion in the second quarter compared to $1.47 billion in the second quarter of 2017.